LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
$0.96
arrow_upward
+0.87%(+0.0082) 1D
$0.95
arrow_downward
-0.59% (-0.0056)todayPre-market
Closed: Sep 30, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
$0.95
High
$0.99
Low
$0.94
Mkt. cap
241.07M
Avg. vol.
1.30M
Volume
450.00
52-wk high
$2.09
52-wk low
$0.91
EPS
-$0.14
Beta
1.54
Shares outstanding
252.91M
No. of employees
75
Open
$0.95
High
$0.99
Low
$0.94
Mkt. cap
241.07M
Avg. vol.
1.30M
Volume
450.00
52-wk high
$2.09
52-wk low
$0.91
EPS
-$0.14
Beta
1.54
Shares outstanding
252.91M
No. of employees
75
News stories
From web sources and news partners
The Motley Fool
·
20 minutes ago
The S&P 500 Is Near an All-Time High but Trading at Its Lowest Valuation in a Year. Nvidia, Alphabet, and Amazon Help Explain Why.
FOREX.com
·
11 hours ago
S&P 500 Forecast: SPX Continues to Drift Away from Record Highs
VT Markets
·
4 hours ago
Dow Jones (DJ30): Key Levels to Watch Before US Non-Farm Payrolls
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc